Estrone (E1): When to Order This Test

What Estrone (E1) Actually Measures

Estrone is one of three endogenous estrogens. It circulates at lower bioactivity than estradiol (E2) but in far greater quantity after menopause, when ovarian estradiol production drops by roughly 90% [1]. Measuring E1 tells clinicians how much residual estrogen a postmenopausal patient is producing, and whether exogenous hormone therapy is shifting the E1-to-E2 ratio into a range that might increase endometrial proliferation.

E1 vs. E2 vs. E3: Which Estrogen Matters When

Estradiol dominates during reproductive years. Estriol (E3) rises during pregnancy. Estrone takes over after menopause. A 2019 review in the Journal of Clinical Endocrinology & Metabolism confirmed that E1 concentrations in postmenopausal women often exceed E2 by a factor of 3 to 5 [2]. Ordering E2 alone in a 62-year-old woman on oral conjugated estrogens will miss the full hormonal picture.

The Role of Adipose Aromatization

Peripheral aromatase in adipose tissue converts adrenal androstenedione to E1. This means body composition directly influences E1 levels. A study published in the Journal of Steroid Biochemistry and Molecular Biology found that postmenopausal women with a BMI above 30 had E1 levels approximately 40 to 60% higher than lean counterparts [3]. The clinical takeaway: obesity raises endogenous estrone independently of any exogenous hormone use.

When Clinicians Should Order E1

The right time to order this test depends on the clinical question. E1 is not a routine screening lab. It becomes useful in specific scenarios where estradiol alone gives an incomplete answer.

Postmenopausal Hormone Therapy Monitoring

Oral estrogen undergoes first-pass hepatic metabolism, generating a disproportionate rise in E1 relative to E2. The Endocrine Society's 2015 clinical practice guideline on postmenopausal hormone therapy notes that oral estradiol produces E1:E2 ratios of 3:1 to 5:1, while transdermal estradiol maintains a ratio closer to 1:1 [4]. Ordering E1 alongside E2 in patients on oral HRT helps determine whether the estrone burden is clinically significant. A persistently elevated E1 in a patient experiencing breakthrough bleeding may prompt a switch to transdermal delivery.

Evaluating Unexplained Postmenopausal Bleeding

Postmenopausal bleeding triggers an endometrial evaluation. But when transvaginal ultrasound shows a thin endometrial stripe and biopsy is benign, an elevated E1 can explain persistent low-grade proliferative stimulus. The American College of Obstetricians and Gynecologists (ACOG) recommends considering estrogen sources, including adipose aromatization, in the workup of recurrent postmenopausal bleeding [5].

Perimenopause and Erratic Cycling

During perimenopause, E2 fluctuates wildly. E1 tends to be more stable because it relies on peripheral conversion rather than follicular activity. Measuring both estrogens during perimenopause can help distinguish between residual ovarian function and adipose-driven estrogen production, guiding decisions about whether contraception is still needed [6].

Suspected Estrogen-Producing Tumors

Granulosa cell tumors and certain adrenal neoplasms secrete estrogens. In postmenopausal women, E1 may rise before E2 does, making it an early signal. The AACE/ACE 2020 guidelines on adrenal incidentalomas recommend estrogen panels that include E1 when hormonal hypersecretion is suspected [7].

Normal Estrone (E1) Ranges by Life Stage

Reference ranges depend on assay methodology, laboratory, and patient demographics. The values below reflect consensus ranges published by major reference laboratories and clinical guidelines.

Premenopausal Women

Follicular phase E1 typically falls between 17 and 200 pg/mL, with luteal-phase values slightly higher at 49 to 345 pg/mL. These numbers track ovarian cycling and are rarely ordered in isolation during reproductive years because E2 is the dominant and more clinically actionable estrogen [8].

Postmenopausal Women

E1 ranges from roughly 10 to 60 pg/mL without hormone therapy. Values above 60 pg/mL in an untreated postmenopausal woman should prompt evaluation for adipose aromatization (check BMI), exogenous estrogen exposure, or, rarely, an estrogen-secreting neoplasm [8].

Men

Male E1 concentrations typically range from 10 to 60 pg/mL. Elevated E1 in men can indicate increased aromatase activity, often associated with obesity or hepatic dysfunction. The Endocrine Society's 2018 guideline on testosterone therapy notes that high E1 in hypogonadal men on testosterone replacement may signal excessive aromatization and can inform aromatase inhibitor dosing decisions [9].

How to Interpret High Estrone Levels

A high E1 result does not exist in a vacuum. Interpretation requires knowing the patient's menopausal status, BMI, medication list, and clinical symptoms.

Obesity-Driven Elevation

This is the most common cause of elevated E1 in postmenopausal women. Aromatase expression in visceral and subcutaneous fat converts circulating androstenedione into estrone at rates proportional to fat mass. A prospective cohort within the Women's Health Initiative (N=438) demonstrated that each 5 kg/m² increase in BMI corresponded to an approximately 15 to 20% increase in circulating E1 [10]. Weight loss through caloric deficit, structured exercise, or pharmacotherapy with GLP-1 receptor agonists can reduce peripheral aromatization and lower E1 over months.

Oral Estrogen Therapy

As noted, first-pass metabolism converts oral estradiol into E1, producing supraphysiologic E1:E2 ratios. If a patient on oral HRT has symptoms of estrogen excess (breast tenderness, bloating, mood lability) alongside an elevated E1, switching to transdermal estradiol bypasses hepatic conversion and typically normalizes the ratio within 4 to 8 weeks [4].

Hepatic and Metabolic Conditions

Liver disease impairs E1 sulfate conjugation and clearance, leading to accumulation. Hypothyroidism can reduce sex hormone-binding globulin (SHBG), increasing free estrogen fractions. Checking liver function tests and thyroid panels alongside E1 prevents misattributing the elevation to ovarian or adrenal sources alone.

How to Interpret Low Estrone Levels

Low E1 carries a different clinical significance depending on whether the patient is premenopausal or postmenopausal.

In Premenopausal Women

Low E1 alongside low E2 and elevated FSH points toward premature ovarian insufficiency (POI). The Endocrine Society's 2015 POI guideline defines the condition as oligo/amenorrhea for 4 or more months with FSH above 25 IU/L on two measurements taken at least 4 weeks apart [11]. Low E1 in this setting confirms diminished estrogen production from both ovarian and peripheral sources. Treatment typically involves hormone replacement to protect bone density and cardiovascular health.

In Postmenopausal Women

Low E1 in a lean postmenopausal woman is expected. It becomes clinically relevant when the patient has accelerated bone loss, vasomotor symptoms, or vulvovaginal atrophy despite being within 5 to 10 years of menopause. These patients may have insufficient peripheral aromatization and benefit from low-dose systemic or local estrogen therapy. The North American Menopause Society (NAMS) 2022 position statement recommends individualized therapy decisions based on symptom burden and risk profile [12].

In Men

Low E1 in men is uncommon and typically clinically irrelevant unless paired with symptoms of estrogen deficiency (joint pain, bone density loss) in the context of aromatase inhibitor overuse during testosterone therapy. Reducing or discontinuing the aromatase inhibitor usually restores E1 within weeks [9].

How to Lower Estrone (E1)

Reducing elevated E1 involves targeting the source of production, the route of exogenous estrogen, or both.

Weight Management

Because adipose aromatization is the primary driver of high E1 in postmenopausal women, sustained weight loss is the most direct intervention. A 2021 analysis in Obesity Reviews showed that a 10% reduction in total body weight corresponded to a 20 to 25% decrease in circulating E1 [13]. Structured caloric restriction, resistance training, or medically supervised GLP-1 agonist therapy can achieve this.

Switching Estrogen Delivery Route

Moving from oral to transdermal estradiol reduces first-pass hepatic conversion to E1. A randomized crossover trial (N=76) published in Menopause found that switching from 1 mg oral estradiol to a 50 mcg/day transdermal patch reduced E1 by 35% while maintaining equivalent E2 levels [14].

Aromatase Inhibitors (Specific Populations)

In breast cancer survivors or men on TRT with excessive aromatization, low-dose anastrozole (0.5 to 1 mg two to three times weekly) suppresses peripheral E1 production. The ATAC trial (N=9,366) established anastrozole's efficacy in reducing estrogen-dependent breast cancer recurrence, with E1 suppression exceeding 80% at standard oncologic doses [15]. Off-label use at lower doses requires careful monitoring of bone density.

How to Raise Estrone (E1)

Intentionally raising E1 is rarely a clinical goal. The objective is usually to restore adequate total estrogen exposure when both E1 and E2 are deficient.

Hormone Replacement Therapy

Oral estrogen therapy raises E1 more effectively than transdermal formulations. Conjugated equine estrogens (CEE 0.625 mg daily) increase E1 by roughly 300 to 500% from baseline in postmenopausal women, based on pharmacokinetic data from the WHI [16]. When E1 augmentation is specifically desired (rare), oral delivery achieves it reliably.

Addressing Underweight and Low Body Fat

In women with very low body fat (BMI <18.5), peripheral aromatization is minimal. Nutritional rehabilitation and weight restoration improve adrenal androgen substrate availability and aromatase expression. This is particularly relevant in functional hypothalamic amenorrhea, where both E1 and E2 recover as body weight normalizes [17].

Ordering Logistics and Paired Labs

E1 is drawn as a simple serum blood test. No fasting is required. Results are typically available within 1 to 3 business days at most reference laboratories.

What to Order Alongside E1

Ordering E1 in isolation limits interpretability. Pair it with estradiol (E2) to calculate the E1:E2 ratio, FSH to confirm menopausal status, SHBG to assess free estrogen fractions, and a lipid panel if evaluating oral estrogen's hepatic effects. In men on TRT, add total testosterone and hematocrit [9].

Timing Considerations

In premenopausal women, draw E1 on cycle day 3 to 5 for baseline comparison with E2 and FSH. Postmenopausal women and men can be tested at any time. For patients on cyclic oral estrogen, draw the sample at trough (just before the next dose) to assess nadir levels.

Assay Methodology Matters

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for E1 measurement, particularly at low postmenopausal concentrations where immunoassays lose accuracy. A 2020 comparison in Clinical Chemistry showed that immunoassays overestimated E1 by 15 to 30% compared to LC-MS/MS at concentrations below 25 pg/mL [18]. Request LC-MS/MS methodology when precision matters for treatment decisions.